Articles tagged "Immunosuppression"

2017 American Transplant Congress
Protease Inhibitor-Based Regimens Are Associated with Inferior Outcomes in HIV-Infected Kidney Transplant Recipients.
B. Shelton,¹ D. Sawinski,² R. Reed,¹ P. MacLennan,¹ S. Mehta,¹ J. Locke.¹
¹University of Alabama at Birmingham, Birmingham; ²University of Pennsylvania, Philadelphia
Background: Excellent outcomes have been demonstrated among HIV-infected kidney transplant (KT) recipients when HIV infection is well-controlled. Protease inhibitors (PI) have significant drug-drug interactions with…
2017 American Transplant Congress
The Phenotypic and Functional Characteristics of a Novel CD11b⁺CD11c⁺F4/80⁺ Monocytic Myeloid-Derived Suppressor Cell Subset.
B. Jiang,^1,2 I. Aljabban,¹ C. Yang,¹ D. Ndishabandi,¹ R. White,¹ P. Russell,¹ J. Madsen,¹ R. Colvin,¹ A. Alessandrini.¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston; ²Dept. of Cardiac Surgery, Second Xiangya Hospital, Central South University, Changsha, China
Background: CD11b+Ly6G-Ly6Chigh monocytic myeloid-derived suppressor cells (M-MDSCs) in mice can promote the apoptosis of T cells and induce regulatory T cells. Novel CD11b+CD11c+F4/80+ cells were…
2017 American Transplant Congress
Efficacy and Safety of Everolimus with Reduced-Exposure Tacrolimus and Corticosteroid Withdrawal in De Novo Pediatric Renal Transplant Recipients: 12-Month Results from the CRADLE Study.
R. Ettenger,¹ B. Tönshoff,¹ H. Tedesco,¹ L. Dello Strologo,¹ S. Marks,¹ L. Pape,¹ E. Martzloff,² B. Rauer,² J. Ng,³ P. Lopez.²
¹A2314 Study Group, Los Angeles; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover
PURPOSE: We present 12-month (M) results from the CRADLE study (NCT01544491) that assessed efficacy and safety of everolimus (EVR) with reduced-exposure tacrolimus (rTAC) and early…
2017 American Transplant Congress
The Feared Five Fungal Infections in Kidney Transplant Recipients: 20-Year Experience at a Midwestern Center.
S. Parajuli, A. Wick, S. Pandeya, B. Astor, J. Smith, A. Djamali, D. Mandelbrot.
University of Wisconsin, Madison, WI
Invasive fungal infections (IFI) are increasing in kidney transplant recipients (KTR). Here we present our experience with five feared IFIs in KTR transplanted between 01/01/1994…
2017 American Transplant Congress
Second-Line Therapy After Standard of Care in Antibody-Mediated Rejection: A Prospective Study.
D. Viglietti, A. Loupy, O. Aubert, E. Pillebout, C. Legendre, D. Glotz, C. Lefaucheur.
Paris Translational Research Center for Organ Transplantation, Paris, France
There is a marked heterogeneity in AMR patients' prognosis after SOC treatment including plasma exchange (PE) and intravenous immunoglobulins (IVIG). We investigated whether a composite…
2017 American Transplant Congress
Felodipine Diminishes Decline in Glomerular Filtration Rate in Lung Transplanted Patients Treated with Cyclosporine: A Randomized Placebo Controlled Trial.
M. Hornum,¹ M. Iversen,² P. Oturai,³ M. Andersen,² M. Zemtsovski,⁴ P. Bredahl,⁴ N. Bjarnason,² K. Christiansen,⁵ J. Carlsen,² C. Møller,⁶ B. Feldt-Rasmussen,¹ M. Perch.²
¹Nephrology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ²Cardiology, Section for Lung Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ³Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ⁴Cardiothoracic Anaesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ⁵Public Health, Section of Biostatics, University of Copenhagen, Copenhagen, Denmark; ⁶Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background. Calcium channel blockers may ameliorate the decline in renal function caused by calcineurin inhibitors in lung transplant (LTX) recipients. We previously demonstrated a 47…
2017 American Transplant Congress
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.
S. Stead,¹ S. Kireta,² S. McInnes,³ P. Rose,¹ S. Jesudason,^1,2 S. Grey,⁴ D. Rojas-Canales,² R. Carroll,^1,2 N. Voelcker,⁴ P. Coates.^1,2
¹Medicine, University of Adelaide, Adelaide, Australia; ²Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ³ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide, Australia; ⁴Transplantation Immunology, Garven Institute of Medical Research, Sydney, Australia
Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…
2017 American Transplant Congress
The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.
K. Minami,^1,3 H. Uehara,¹ A. Elkhal,¹ S. Bae,³ J. Reder,² B. Houser,² P. Kang,³ S. Tullius.¹
¹Transplant Surgery Division, Brigham and Women's Hospital, Boston, MA; ²Celdara Medical, LLC, Lebanon, NH; ³Beth Israel Deaconess Medical Center, Boston, MA
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…
2017 American Transplant Congress
The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.
A. Hart,^1,2 S. Gustafson,² A. Wey,² N. Hadley,² A. Israni.²
¹Hennepin County Medical Center, Minneapolis; ²Scientific Registry of Transplant Recipients, Minneapolis
Medicare coverage for kidney transplant recipients aged <65 years in the US ends 3 years posttransplant, but a significant proportion of recipients remain on Medicare…
2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
G. Gu, H. Hang, Q. Xia.
Department of Hepatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…